Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer

Daniel Sur 1,2,† , Andrei Havasi 2,† , Calin Cainap 1,2,† , Gabriel Samasca 3,*,† , Claudia Burz 2,3,† , Ovidiu Balacescu 1,4,† , Iulia Lupan 5,† , Diana Deleanu 3,† and Alexandru Irimie 6,7,†

1 11th Department of Medical Oncology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400015 Cluj-Napoca, Romania; dr.geni@yahoo.co.uk (D.S.); calincainap2015@gmail.com (C.C.); obalacescu@yahoo.com (O.B.)
2 Department of Medical Oncology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania; havasi.andrei@gmail.com (A.H.); cburz@yahoo.fr (C.B.)
3 Department of Immunology and Allergology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400162 Cluj-Napoca, Romania; deleanudiana@yahoo.com
4 Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania
5 Department of Molecular Biology and Biotechnology, Babes-Bolyai University, 400084 Cluj-Napoca, Romania; iulia.lupan@gmail.com
6 11th Department of Oncological Surgery and Gynecological Oncology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania; airimie@umfcluj.ro
7 Department of Surgery, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 400015 Cluj-Napoca, Romania
* Correspondence: Gabriel.Samasca@gmail.com
† All authors contributed equally to this work.

Received: 24 December 2019; Accepted: 7 January 2020; Published: 9 January 2020

Abstract: Chimeric antigen receptor (CAR) T-cell therapy represents a new genetically engineered method of immunotherapy for cancer. The patient’s T-cells are modified to express a specific receptor that sticks to the tumor antigen. This modified cell is then reintroduced into the patient’s body to fight the resilient cancer cells. After exhibiting positive results in hematological malignancies, this therapy is being proposed for solid tumors like colorectal cancer. The clinical data of CAR T-cell therapy in colorectal cancer is rather scarce. In this review, we summarize the current state of knowledge, challenges, and future perspectives of CAR T-cell therapy in colorectal cancer. A total of 22 articles were included in this review. Eligible studies were selected and reviewed by two researchers from 49 articles found on Pubmed, Web of Science, and clinicaltrials.gov. This therapy, at the moment, provides modest benefits in solid tumors. Not taking into consideration the high manufacturing and retail prices, there are still limitations like increased toxicities, relapses, and unfavorable tumor microenvironment for CAR T-cell therapy in colorectal cancer.

Keywords: Chimeric antigen receptor (CAR)T-cell; colorectal cancer; immunotherapy; toxicity; trials

1. Introduction

Colorectal cancer (CRC) is one of the most common cancers in 2019 and ranks second for global cancer-related deaths [1]. The prognostic for advanced and metastatic disease is still modest. Approximately one-third of patients are diagnosed with metastatic disease [2]. The median overall survival (OS) with metastasis is about 30 months [3]. Chemotherapy combinations can prevent metastasis and improve OS in first-line treatment of CRC patients [4–6]. Despite having multiple lines of treatment for metastatic disease, OS remains low and decreases substantially with time. The addition of targeted therapies achieved a better clinical outcome for these patients. Fluoropyrimidinedoublet...
(FOLFOX/CAPOX or FOLFIRI/CAPIRI) associated with biologic agents targeting the epidermal growth factor receptor (EGFR) for RAS wild-type tumors or angiogenesis (VEGF) represent the backbone of first and second-line treatment schedule. Targeted therapies such as cetuximab and panitumumab for RAS wild-type patients or antiangiogenic drugs like bevacizumaborziv-aflibercept are the mainstay of metastatic colorectal treatment [7]. The real struggle for clinicians is to find the right balance between standard chemotherapy and new options. Finding the correct management with limited toxicities and increased quality of life and OS is the goal.

A more accurate understanding of the interaction between the immune system and tumor cells has changed therapeutic guidelines by developing new drugs. Immunotherapy with anti-PD-1 mAbs (monoclonal antibodies) pembrolizumab and nivolumab, and anti-CTLA-4 mAbs like ipilimumab have shown promising results in metastatic CRC [8] and are US Food and Drug Administration (FDA) approved for microsatellite instability-high (MSI-H) CRC [9]. The combination of nivolumab and ipilimumab also seems to improve OS and progression-free survival (PFS) in MSI-H metastatic CRC patients and has an acceptable safety profile [10]. Immunotherapy seems to be less effective in CRC compared with other tumor localizations, especially in the mismatch repair (MMR) proficient phenotype and microsatellite stable (MSS) profile [11].

Even after current treatment strategies with chemotherapy, targeted therapies, and immunotherapies, CRC patients develop recurrent disease [12]. Scientists are trying to develop stratification methods and novel treatments for CRC patients. In addition to ongoing clinical trials [9] there are new experimental options. Research in miRNAs [13] and exosomal miRNAs [14] has been promising in the last few years in CRC research. Regarding a CRC vaccination [15], the need for individualization and organized vaccination strategies are still a working process.

Chimeric antigen receptor (CAR) T-cell immunotherapy has become more popular in the last decade in the war against cancer. CARs are laboratory made immune-receptors that modify lymphocytes to target and eliminate cells that express a specific antigen on their surface. T-cells harvested from the patient’s own blood (autologous) or healthy donor’s blood (allogeneic) are genetically engineered to express a specific CAR. For safety reasons, CAR T-cells are conceived to target a specific antigen for the tumor cell and not the normal cell [16]. We investigated the role of CAR T-cells in CRC. We briefly present the main mechanism of action of CAR T-cells, toxicities and administration problems, and implications for other solid tumors. In this review, we focus on literature data to understand if CAR T-cell therapy has a place in the therapeutic sequences of CRC. Data that we present herein confirms that CAR T-cell therapy is a viable method for CRC treatment with the right antigen selection and a combinatorial therapeutic approach.

2. Search Criteria

Pubmed, Web of Science, and clinicaltrials.gov were searched with the MeSH terms and keywords chimeric antigen receptor T-cell and colorectal cancer. All the studies that matched were included through August 2019. By reviewing the titles and abstracts, the preliminary screening process identified 49 possible relevant publications. Two separate researchers double-checked the studies included in this review. After eliminating duplicates, other topic articles, non-research work, non-English written papers, and uncompleted reports, 22 articles were found to be relevant to CAR T-cell therapy in CRC.

3. Overview and Mechanism of Action of CAR T-Cells

Although CAR T-cell technology was described more than twenty years ago by Gross and colleagues [17], clinical implementation came rather recently. The main interest of CAR T-cell research was to find an active function of T lymphocytes targeting and destroying cancer cells [18]. In recent years, CAR T-cell therapy has come a long way as a personalized immunotherapy option. CAR T-cell therapy trials have achieved long term remissions and complete responses in cancer patients [19]. The process of CAR T-cell therapy is shown in Figure 1.
CAR T-cell therapy manipulates the immune system by collecting and using immune cells to treat cancer. The T-cell is genetically engineered to express special chimeric immunoreceptors (CARs) that give T-cells the ability to target a specific protein. For example, CD19 CAR T-cells are designed to develop CARs against CD19 antigen has a role both in lymphoma and leukemia [20]. Unlike the classical T-cell receptor design that has dual intracellular alpha and beta chains linked with a CD3 complex and associates with the major histocompatibility complex, the CAR design also has an extracellular domain consisting of a single-chain variable fragment (scFv) and does not need the MHC to target specific tumor antigens [21].

CAR T-cell therapy is a personalized immunotherapy method that has to follow certain steps to be used in the clinic. After the patient’s immune cells are engineered in vitro, they must be re-infused to complete the process. More descriptively, the whole process consists of the extraction of normal T-cells from the peripheral blood of the patient by leukapheresis, and then CARs are integrated into the T-cells in the laboratory. Afterward follows an in vitro process of cultivation and expansion of the CAR T-cells. The final actions consist of the reinfusion of the final product of CAR T-cells back into the patient and the close monitoring for acute side effects [22]. After reinfusion, the engineered CAR T-cells proliferate and start a killing spree directed towards the tumor cells that bear the specific antigen the CARs are directed against [23]. To optimize efficacy and to minimize toxicities, current protocols suggest conditioning chemotherapy [24].

Considering their structure and production, we are currently in the fourth evolving generation of CAR T-cells. The first generation expressed only the CD3ζ molecule for signaling and was unsuccessful in clinical trials [25]. The second and the third generation had co-stimulatory molecules like CD28, 4-1BB, OX40, or CD27 in addition to CD3ζ to boost cytokines. The fourth generation of CAR T-cells is being designed to overcome the inhibitory effect of the tumoral microenvironment. Having the additional property of secreting cytokines like IL-2 and IL-12, it seems to have a better outcome in solid tumors [26].

There is an increasing number of clinical trials involving CAR T-cell therapy for breast, colorectal, prostate, and renal cancer [27]. Despite the high interest in this treatment, a significant limitation remains accessibility and cost. In 2017, the FDA approved CAR T-cell therapy for several hematological malignancies. Axicabtagenlecleucel (Yescarta) [28] was approved for diffuse large B-cell lymphoma in the context of refractory or relapsed disease. It was also approved in the context of high grade or mediastinal large B-cell lymphoma. Tisagenlecleucel (Kymriah) [29], a CD19 directed 4-1BB/CD3ζ CAR T-cell therapy, was approved rapidly for refractory and relapsed acute lymphoblastic leukemia for children and young adults. Later it was also approved for diffuse large B-cell lymphoma and high-grade
B-cell lymphoma. With the hope of finding suitable target antigens for expanding CAR T-cell therapy to other hematological malignancies and solid tumors, many large clinical trials are needed.

4. Current Toxicities and Administration Difficulties of CAR T-cells

It is now well established that one of the most significant problems of CAR T-cell therapy is toxicity. There is a clear difference between the toxicity that is encountered in liquid tumors compared to solid tumors. The outcome after treatment with CAR T-cells for solid tumors is still modest. The main side effect of CAR T-cell therapy in hematological tumors is cytokine release syndrome (CRS) [30]. There are also other toxicities like neurotoxicity, anaphylaxis, and on target/off tumor effects [31].

For cytokine release syndrome (CRS), there are a vast number of clinical symptoms. It is not uncommon for the patients to face nausea, malaise, fevers, cardiac dysfunction, hypotension or tachycardia, disseminated intravascular coagulation, or respiratory/renal impairment [32]. This syndrome correlates with CAR T-cell dose, response to therapy, and disease burden [33,34]. CRS can be explained as a response to the torrent of inflammatory cytokines released by the numerous activated CAR T-cells. As cytokines are challenging to evaluate, C-reactive protein (CRP) is used as a marker to assess the severity of CRS [35]. Treatment consists of administration in the first instance with high-dose steroids, vasopressors, respiratory support, and supportive care. Tocilizumab, which is an anti-IL-6R antibody, can be a beneficial treatment for some cases [36].

Neurotoxicity is generally reversible and consists of symptoms of confusion, aphasia, seizures, and delirium. Even though the cause of neurotoxicity is unknown, there are two conjectures about this toxicity in CAR T-cell therapy. The first is related to the high levels of cytokines liberated, and the second to direct injury of the neurological tissue [37,38].

On target/off tumor effects that appears more often in the treatment of solid tumors are caused by the presence of the target antigen for CAR T-cells on cancer cells and also in low levels in normal tissue [39]. CAR T-cells acting on normal cells cause this sort of toxicity, underscoring the importance of choosing the right target antigen for therapy.

A recent paper by Shah and Fry [40] described the barriers that CAR T-cell therapy faces to induce long-term remission. The first of the four barriers is the failure to achieve remission either by problems in manufacturing, infusion, or CAR T-cell activation and expansion. Lack of access is an issue, as is the cost of treatment. The second barrier leading to disease relapse is constituted by antigen modulation, which enables antigen escape responsible for resistance. This phenomenon is also found in solid tumors. The third barrier is the toxicity of CAR T-cell therapy including cytokine release syndrome or neurotoxicity. Finally, there are issues of adapting CAR T-cell therapy for other types of hematological malignancies or solid tumors. For instance, anti-CD19 CAR T-cell therapy for adults with lymphoma is correlated with a good response compared with the clinical response of CAR T-cell therapy in leukemia and pediatric malignancies.

Of course, there are a series of limitations to CAR T-cell therapy like tumor type, patient population, lymphodepletion regimen, and CAR T-cell design. Developing guidelines [41] and having an early intervention concerning toxicity using adequate grading scales [42] can improve the results of this promising method. However, data from the literature reports one severe event of a patient with metastatic CRC that died after receiving Trastuzumab CAR T-cell therapy associated with IL-2 after lymphodepletion chemotherapy. The cause of death was rapid respiratory failure onset due to reactivity against pulmonary tissue [43].

Suicide genes or elimination genes come as a solution for these sorts of toxicities. Incorporating genes like Herpes simplex virus thymidine kinase or Escherichia coli nitroreductase have some downfalls. Introducing these systems into limited genetic space can cause immunogenic effects resulting in premature elimination of CAR T-cells and subsequent toxicity [44]. Although suicide gene engineering is part of the current clinical trials, proper procedures have not been established in clinical practice.
5. CAR T-Cell Therapy in Solid Tumors

CAR T-cell therapy is increasingly becoming a key player in the treatment of malignant diseases. While clinical trials are still in high demand, the use of CAR T-cells in the therapy of hematologic oncology such as acute lymphoblastic leukemia or lymphoma is generally accepted worldwide [45]. By targeting CD19 antigen on B-cells using CAR T-cell therapy, clinicians attained durable remissions and clinical response in patients with B-cell non-Hodgkin lymphoma and acute lymphoblastic lymphoma [46]. Efforts are being made to provide CAR T-cell treatment for other types of lymphoma and myeloma.

Most published work has mainly focused on hematologic disease, and results concerning solid tumors have insufficient evidence for clinical use. There are various challenges for CAR T-cell therapy in solid tumors.

Recent trials moved their attention to solid tumors by targeting different surface proteins. From the multitude of targeted surface proteins like human epidermal growth factor receptor 2 (HER2), diganglioside (GD2), carcinoembryonic antigen (CEA), mesothelin, and fibroblast activation protein (FAP), only the first two (GD2 and HER2) were part of positive trials [47]. Only one trial using GD2 CARs for neuroblastoma resulted in complete remission [48]. Using HER2 CARs for sarcoma or HER1 for advanced relapsed or refractory non-small cell lung cancer showed stable disease or partial response in the patients enrolled [49,50].

Several biological barriers exist in the process of successful trafficking of T-cells from blood to the stromal elements of solid tumors. These barriers could explain the different results of CAR T-cell therapy in hematological malignancies compared to solid tumors. Even if the prerequisite of trafficking and infiltration is done, T-cells face some natural obstacles and become defective. One of the most critical features is that CAR T-cells first have to identify the proper tumor-associated antigen (TAA). Then they have to face the unwelcoming tumor microenvironment. The tumor microenvironment interferes with the penetration of CAR T-cells into stromal tumor mass, promoting an immunosuppressive milieu [51]. Afterward, CAR T-cells encounter cytokines and soluble inhibitory factors. Suppressive immune cells like regulatory T-cells (Treg) or tumor-associated macrophages (TAM) and other negative regulatory systems also step in the way of the activated T-cells [52,53].

Researchers try to understand the interactions between the hostile microenvironment and the host’s immune system with all its immunomodulatory effects. These two seem to be the culprits for the resistance mechanisms of CAR T-cell therapy in solid tumors. By changing the design of CAR T-cells incorporating co-stimulatory molecules, ligands, targeted therapies, or immunomodulatory agents can improve the clinical outcome [54]. Wang et al. [55] suggest that targeting more than one antigen and building a dual-targeted CAR can overcome the risk of antigen escape relapse and diminish the effect of antigen heterogeneity. Off-target toxicity is still a big issue to consider in classically designed CAR T-cells and in novel dual-targeted cells [56]. PD-1/PD-L1 blockade may be a successful plan for boosting the potency of CAR T-cell therapies in solid tumors [57].

Recent data assume that new mechanisms of antigen recognition through CARs can make a difference in solid tumors. Trying to modulate the immunological synapse formation can improve efficacy. The density of the target antigen can also control the efficacy of treatment in solid tumors [58].

Personalized modification of CAR T-cell construction, finding a more suitable T-cell subset for engineering, incorporating anti-cancer cytokines, manipulating PD1/CTLA4 checkpoints, infiltrating soluble immunosuppressive factors like TGF-β and IL10, are some proposed changes that can make a difference [59]. An opportunity for modifying CAR design and construction for use on other cells than immune cells like the design of a tumor cell vaccine exists as a promising research direction [60].

Many experts now contend that we should change the general approach of CAR-T cell therapy in solid tumors. We should focus more on CAR-T local delivery and on associating chemotherapy or immune checkpoint inhibitors with the regimen for metastatic disease. Targeting two different antigens seems a reliable solution to broadening the spectrum of therapeutics. Scientists should
consider developing CAR T-cell therapy for adjuvant treatment after resection to prevent recurrence or metastasis [61].

6. CAR T-Cell Therapy in Gastrointestinal Malignancies

Gastrointestinal tumors are the most common types of human cancers encountered worldwide. There is a modest improvement in survival by integrating novel chemotherapeutic and radiotherapeutic schedules. Due to the increasing burden of cancer, it is necessary to incorporate alternative strategies like CAR T-cell therapy to improve outcomes. CAR T-cell therapy has shown modest benefits in solid tumors. There are several attempts to find the right formula for CAR T-cells in gastrointestinal tumors.

6.1. Pancreatic Cancer

CAR T-cell therapy is studied intensively in pancreatic cancer. Like most solid tumors, pancreatic cancer presents a series of tumor-specific antigens that can serve as promising targets for CAR T-cell therapy. Overexpressed antigens like carcinoembryonic antigen, mesothelin, human epidermal growth factor receptor 2 (HER-2), and mucin 1 (MUC1) show great potential [62–64]. With this in mind, an article from 2017 [65] summarized the possible targets of CAR T-cells in pancreatic cancer and added CD24, prostate stem cell antigen, and natural killer receptors for the construction of CARs. By showing high expression, mesothelin appears to be the most promising target for CARs [66–69]. Other research [70] focused on blocking IL-10 with the purpose of tackling the immunosuppressive effect of the tumor microenvironment and enhancing mesothelin CAR T-cell activity. A phase I trial showed good results using mesothelin mRNA CAR T-cell therapy against pancreatic cancer metastases. The trial also revealed a satisfactory safety profile [71]. In lung metastases from pancreatic cancer, mesothelin CAR T-cell design showed impressive results [72]. Combining mesothelial CAR T-cells with cytokine-armed oncolytic adenovirus expressing TNF-α or IL-2 enhanced the efficacy of the chimeric antigen receptor therapy [73].

Another approach was targeting prostate stem cell antigen and protecting cells from immunosuppressive cytokines by manipulating the tumor microenvironment [74]. Abate-Daga and colleagues [75] proposed targeting prostate stem cell antigen in a humanized mouse model of pancreatic cancer. Modulating the dense stromal surroundings of pancreatic cancer and adapting the cells to the tumor microenvironment seems like proper options to improve clinical benefit [76]. With a different CAR construct, humanized CD47-CAR T-cells eliminated with excellent specificity ovarian, cervical, and pancreatic cancer cells [77]. Zhang E et al. [78] constructed a dual CAR-modified T-cell to eradicate AsPC-1 pancreatic cells that have high expression of carcinoembryonic antigen (CEA) and mesothelin (MSLN). A study using switchable CAR T-cells to target HER-2 on patient-derived xenograft models from patients with aggressive metastatic pancreatic cancer showed considerable potency [79]. Whilding et al. hypothesized that controlling IL-8 might control tumor burden in solid tumors by accomplishing a higher therapeutic activity in pancreatic and ovarian tumor xenografts. This result was possible by expressing IL-8 receptors CXCR1 and CXCR2 in a CAR T-cell construct to target the tumor-associated αvβ6 integrin [80].

These findings mentioned above confirm that CAR T-cell therapy for pancreatic cancer is developing fast, and its potential needs to be confirmed in future trials and studies [81,82].

6.2. Hepatocellular Carcinoma

Accumulating data show that hepatocellular carcinoma has limited therapeutic options. Hoseini et al. outline the possibility of using CAR T-cell therapy and bispecific antibodies for hepatocellular carcinoma treatment. Bispecific antibodies can redirect natural killer cells toward cancer cells paving the way for CAR T-cells to infiltrate the tumor site [83]. Although no clinical CAR T-cell trials for hepatocellular cancer have been completed to date, some preclinical and clinical evidence suggests a potent antitumor activity for therapies targeting CEA, MUC-1, and GPC-3 antigens [84,85]. Most results in experimental studies have come from targeting GPC-3, either using an inducible
armored IL-12 construct [86] or by directly eliminating GPC-3 positive HCC cells [87,88]. Another approach was by a dual-CAR construct expressing GPC-3 and asialoglycoprotein receptor 1 (ASGR1) with less toxicity [89]. One study [90] proved in vitro and in vivo that by disrupting programmed death 1 receptor (PD-1) on the Glypican-3 (GPC3)-targeted second-generation CAR T-cells showed a much stronger activity against hepatocellular carcinoma.

For immunotherapy to be effective in hepatocellular carcinoma, it needs a more combinatorial perspective by associating checkpoint inhibitors with immune cell therapy [91,92]. There is still a long way for CAR T-cell therapy in HCC from bench to bedside.

6.3. Gastric Cancer

There is little evidence about CAR T-cell therapy in gastric cancer. The data available is rather recent proposes several targets for CARs. The first study showed that the construction of a CAR T-cell that targets monoclonal antibody 3H11 had a promising response in gastric cancer, although it does not overcome the current biological barriers of solid tumors [93]. The second [94] study used the fact that folate 1 receptor (FOLR1) expression is overexpressed in gastric cancer in comparison to normal tissue. The results confirmed that FOLR1 CAR T-cells could recognize and exhibit anti-tumor activity in FOLR1-positive gastric cancer cells. The third study chose natural killer group 2D(NKG2D) ligand as a target for a second-generation CAR design. The final NKG2D-CAR T-cells compound showed cytolytic activity against gastric cancer cells. Adding cisplatin increased the responsiveness to the CAR T-cell construct [95]. The latest research concerning gastric cancer involved targeting claudin18.2 for their CAR T-cell construction [96].

6.4. Esophageal Cancer

Clinical trials of CAR T-cell therapy in thoracic malignancies are scarce. The main targets for CARs of esophageal cancer were epithelial cell adhesion molecule (EpCAM) and HER2 [97]. We found one experimental study that targeted EphA2 for esophageal squamous cell carcinoma (ESCC) CAR T-cell construction. The EphA2 CAR T-cells showed a better esophageal cell kill ratio than T-cells and were also dose-dependent [98].

6.5. Biliary Tract Cancer

Immunotherapy has shown clinical benefit in hepatobiliary cancer but only in a small subset of patients. Recently investigators have examined the possible implication of CAR T-cells in biliary tract cancer [99]. CAR T-cell therapies studies and trials in biliary tract cancers propose mesothelin [100], EGFR [101,102], or HER2 [103] as targets because of their tendency to be overexpressed in these malignancies.

7. CAR T-Cell Therapy Studies for CRC

Potential targets for CAR T-cell therapy in CRC are shown in Figure 2. Hege et al. [104] reported one of the first human trials concerning CAR T-cells for metastatic CRC. It consisted of two phase 1 trials (C9701 and C9702), which used the same CART72 cells. CART72 cells were designed as first generation CAR T-cells that targeted tumor-associated glycoprotein (TAG)-72 and included a CD3-zeta intracellular signaling domain. The difference between the two trials was the administration of CART72. Trial C9701 had the CART72 administrated intravenously in an escalating dose, and trial C9702 had direct hepatic artery infusion in patients with colorectal liver metastases. The results showed a good safety profile despite a short-term persistence in blood, and the fact that trafficking to tumor tissue was limited. In addition, CART72 immunogenicity was associated with fast clearance after infusion of CAR-T cells.
The transfection of peripheral blood lymphocytes (PBL) with retroviruses proved low efficiency. The study revealed that anti-4-1BB monoclonal antibody could augment the antitumoral activity of CAR T-cells in colorectal tumor control. Complete tumoral eradication could not be obtained in interferon γ deficient T-cells.

Oncoretroviral transfection is exceedingly useful in transducing chimeric T-cell receptor in fast-dividing T-cells, but involves quickly multiplying cells and production of high virus titers. The transfection of peripheral blood lymphocytes (PBL) with retroviruses proved low efficiency. Lentiviruses can transduce non-dividing cells. The association of a lentivirus with vesicular stomatitis virus G protein gave highly efficient PBL transduction of chimeric T-cell receptor. PBL-modified cells proliferated in vitro on exposure to CEA-positive cells and showed an antitumoral effect on CEA-positive CRC mouse models.

CAR T-cell therapy was associated with anti-4-1BB on human-Her2 mouse models to enhance the anti-tumor activity. The study revealed that anti-4-1BB monoclonal antibody could augment the effect of CAR T-cell therapy by suppressing the host’s tumor microenvironment. This protocol could be of use for solid tumors like CRC after first line adoptive therapy failure.
Daly et al. conducted one of the first studies using CAR T-cell therapy for CRC [114]. The study redirected T-cells using a chimeric receptor which recognized epithelial glycoprotein 40 (EGP40) as the selected antigen. Results of another study showed that MiR-153 has the property to enhance CAR T-cell therapy in CRC. MiR-153 inhibits indoleamine 2,3-dioxygenase 1 (IDO1) in CRC cells and acts as a tumor suppressor [115].

Intraperitoneal infusion of CAR T-cells combined with depleting antibodies against myeloid-derived suppressor cells (MDSC) and regulatory T-cells (Treg) showed considerable results in CRC mouse models. Regional delivery of CAR T-cell compared to systemic infusions resulted in enhanced anti-tumor effects for peritoneal carcinomatosis [116]. For peritoneal carcinomatosis, an EpCAM targeting CAR T-cell construct exhibited anti-tumor efficacy for mouse models of human ovarian cancer and CRC [117]. EpCAM proved to be a suitable target for CARs in a xenograft mouse model. The EpCAM CAR T-cell delayed tumor growth and displayed an excellent safety profile [118]. Deng et al. [119] showed that NKG2D CAR T-cells exhibit specific cytotoxicity in human CRC cell lines. The study was conducted in vivo and in vitro showing promising immunotherapeutic activity. In a patient-derived xenograft mouse model with CRC, HER-2 CAR T-cell therapy selectively killed HER-2 positive tumor cells. Besides the establishment of a new study model for immunotherapy, the study revealed that the cells were protected from tumor re-challenge after infusion [120].

Knowing that the hostile microenvironment is part of the resistance system of CAR T-cell therapy in CRC, a study evaluated the implication of Interferon-alpha/beta receptor alpha chain (IFNAR1). It showed that genetic or pharmacologic stabilization of IFNAR1 can influence tumor growth and can enhance chimeric antigen receptor T-cell therapy in solid tumors [121].

One preliminary study that is part of an ongoing clinical trial showed that CD133 could be an interesting target for CAR T-cell therapy. Infusion with CAR T-133 cells for positive CD133 metastatic pancreatic cancer, hepatocellular cancer, and CRC showed effective response with tolerable toxicity. Another practical implication was that by repeating cell infusions, a more extended period of stable disease resulted [122].

From another perspective, the use of antibiotics proved to diminish the effect of CD4+ CAR T-cells in a CRC mouse model. Chemotherapy with cyclophosphamide was used for the conditioning regimen in mice [123]. Using colorectal carcinoma cells positive for EGP-2 researchers proved that there was no significant difference in T-bodies activity with either ζ-chain or the γ-chain in chimeric T-cell receptor construction. This confirmed the option of using both ζ-chain or γ-chain in clinical trials [124]. Sasaki et al. generated gene-modified Tc1 and Th1 cells from one CRC patient. These gene-modified T-cells showed high cytotoxicity and produced INF-γ in the tumors expressing CEA [125].

### CAR T-Cells Ongoing Trials in CRC

Several ongoing trials (Table 1) are investigating the use of CAR T-cell in the treatment of CRC. A phase I, open-label clinical trial is assessing the safety, cellular kinetics, and efficiency of CYAD-101, an allogenic CAR T-cell therapy targeting ligands of NKG2D, administered concurrently with FOLFOX in patients with unresectable metastatic CRC [126].

Two clinical trials are researching the efficiency and safety of NKR-2 CAR T-cells in metastatic CRC patients. The first trial with NCT03370198 ID [130] investigates the biweekly hepatic transarterial administration of NKR-2 CAR T-cells in patients with unresectable liver metastases. On the other hand, the second trial [131] studies the safety and efficiency of NKR-2 cells administered alongside FOLFOX in potentially resectable liver metastases from CRC.
Table 1. Ongoing clinical trials of CAR T-cell therapy conducted in CRC.

| Target Pathology | Trial ID       | Study Phase | Administration | Patient Number | Year | Reference |
|------------------|----------------|-------------|----------------|----------------|------|-----------|
| EGFR IL-12       | NCT03542799    | I/II        | Systemic       | 20             | 2018 | [127]    |
| EGFR             | NCT03152245    | I/II        | Systemic       | 20             | 2017 | [128]    |
| NKG2D            | NCT03692429    | I           | Systemic       | 36             | 2018 | [126]    |
| CEA              | NCT02959151    | I/II        | Vascular       | 20             | 2016 | [129]    |
| NKG-2            | NCT03370198    | I           | Hepatic        | 18             | 2017 | [130]    |
| MUC-1            | NCT02617134    | I/II        | Systemic       | 20             | 2015 | [131]    |
| HER2             | NCT02713984    | I/II        | Systemic       | 60             | 2016 | [133]    |
| CEA              | NCT03682744    | I           | Intraperitoneal | 18             | 2018 | [135]    |
| C-MET            | NCT03638206    | I/II        | Systemic       | 73             | 2018 | [136]    |
| EpCAM            | NCT03013712    | I/II        | Vascular       | 60             | 2017 | [137]    |
| CD133            | NCT02541370    | I/II        | Systemic       | 20             | 2015 | [138]    |
| CEA + CEA        | NCT02850536    | I           | Hepatic        | 5              | 2015 | [139]    |
| HER2             | NCT03740256    | I           | Systemic & Intratumoral | 39 | 2018 | [140]    |
| CEA + adenocarcinoma | NCT02416466  | I           | Hepatic        | 8              | 2015 | [141]    |

EGFR and EGFR IL-12 CAR T-cell safety and feasibility in the treatment of metastatic CRC are also being currently evaluated in phase I and II studies [127,128]. Various trials are investigating the use of anti-carcinoembryonic antigen targeted CAR T-cells in several CEA-positive malignancies, including CRC. Concerning the administration protocol, trials with CEA as a target for CARs prefer systemic, hepatic transarterial administration, vascular interventional, or intraperitoneal infusion. In addition to metastatic colorectal cancer, CEA is used as a target for other solid tumors like lung, gastric, pancreatic, hepatocellular, or breast cancer [129,134,135,139,141].

Anti HER2 CAR T-cells are studied in HER2 positive cancers in preclinical studies [133]. NCT03740256 [140] phase 1 trial is investigating the efficiency and safety of HER 2 chimeric antigen receptor-modified adenovirus-specific cytotoxic T lymphocytes administered in association with intratumoral injection of CAdVEC, an oncolytic adenovirus. The administration of CAdVEC is proposed to create a pro-inflammatory tumor microenvironment that will promote the recruitment and expansion of the transferred CAR T-cells.

The use of CAR T-cells targeted against MUC1 is proposed for relapsed or refractory solid tumors like glioma, metastatic colonic adenocarcinoma, and gastric cancer, which exhibit confirmed MUC1 positive status [132]. C-MET appears as a target for colorectal cancer, hepatoma, ovarian, and renal cancer in phase I/II CAR T-cell trial with over 73 participants. The trial consists of a multi-target gene-modified CAR T/TCR T-cell that includes ten different tumor-specific antibodies [136]. Other ongoing trials use CAR T-cells targeting EpCAM [137], or CD 133 [138] -positive CRC to assess safety and feasibility for both solid tumors like colorectal cancer as well as hematological malignancies. The completion date for the trial concerning CD133 targeted CAR T-cells is December 2019. Preliminary
data suggest that CD133 is an attractive therapeutic target for relapsed or refractory malignancies, including CRC. The trial underlines the safety profile and efficient activity of CART-133 therapy for CD133 positive metastatic cancers.

8. Conclusions and Further Perspectives

Despite the recent developments in CAR T-cells therapy for hematological malignancies, the use of these therapies in solid tumors is still debatable. CAR T-cell therapy has become mainstream for hematologists even though there are a series of limitations to the treatment. Adoptive cell therapy should be conducted in highly specialized clinical centers with staff that is trained in dealing with common side effects. Product manufacturing and infrastructure for clinical implementation is well accepted in many centers worldwide, but a more specific focus on solid tumors is in need.

As summarized in this review, there are many promising CAR T-cell therapeutic strategies for colorectal cancer that have shown success in preclinical models or early phase clinical trials. The primary role of immunotherapy as CAR T-cell is confirmed in the durable response of the treatment. One of the major issues is that durable response is available only for a small subset of patients in colorectal cancer. The objective of CAR T-cells therapy is to find the right target for CARs or the right combination with novel checkpoint inhibitors or monoclonal antibodies. This approach can help to broaden the spectrum of patients that can obtain a sustainable clinical benefit.

Chimeric antigen receptor T-cell therapy is an immunological concept that has been in development for years. Treatment of hematological malignancies with this method has changed the way we treat cancer and makes us see the possibilities of treating solid tumors. Recent data show that CAR T-cell therapy could be useful in gastrointestinal tumors in colorectal, pancreatic, gastric, or hepatobiliary cancer. This has opened the door for further studies and trials, although there is extensive work needed to implement this therapeutic method in colorectal cancer. Colorectal cancer is one of the most studied cancers and one of the few with promising immunotherapy results. CAR T-cell therapy will hopefully deliver substantial clinical benefit for colorectal cancer.

Author Contributions: Conceptualization, D.S., C.B., A.H., O.B. and C.C.; methodology, D.S., O.B., C.C., G.S. and D.D.; validation, D.S., O.B., A.H. and C.B.; formal analysis, C.B., I.L., G.S., C.C.; investigation, A.H., I.L., G.S., D.D.; resources, A.I., C.B., C.C. and D.D.; data curation, O.B., A.H., G.S., I.L.; writing—original draft preparation, D.S., A.H., C.C., C.B.; writing—review and editing, D.S., A.I., D.D., G.S.; visualization, D.S., O.B., G.S., I.L., D.D.; supervision, A.I., C.C., C.B., D.D.; project administration, A.I., I.L., C.B., D.D.; funding acquisition, C.B., C.C., A.I., D.D.; please turn to the CRediT taxonomy for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported. All authors have read and agreed to the published version of the manuscript.

Funding: The article is funded by the Romanian Society of Radiotherapy and Medical Oncology (RSRMO).

Acknowledgments: Professional editing, B. Peace, PhD. The authors D.S., C.C., and O.B. were supported by the BIOGENONCO grant, 10/01.09.2016 (MySMIS-Code: 105774).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
2. Miller, K.D.; Siegel, R.L.; Lin, C.C.; Mariotto, A.B.; Kramer, J.L.; Rowland, J.H.; Stein, K.D.; Alteri, R.; Jemal, A. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 2016, 66, 271–289. [CrossRef] [PubMed]
3. Van Cutsem, E.; Cervantes, A.; Adam, R.; Sobrero, A.; Van Krieken, J.H.; Aderka, D.; Aranda Aguilar, E.; Bardelli, A.; Benson, A.; Bodoky, G.; et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016, 27, 1386–1422. [CrossRef] [PubMed]
4. Cassidy, J.; Clarke, S.; Diaz-Rubio, E.; Scheithauer, W.; Figer, A.; Wong, R.; Koski, S.; Rittweger, K.; Gilberg, E.; Saltz, L. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br. J. Cancer 2011, 105, 58–64. [CrossRef]
5. Yee, N.S. Update in Systemic and Targeted Therapies in Gastrointestinal Oncology. *Biomedicines* 2018, 6, 34. [CrossRef]

6. Marques, R.P.; Duarte, G.S.; Sterrantino, C.; Pais, H.L.; Quintela, A.; Martins, A.P.; Costa, J. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. *Crit. Rev. Oncol. Hematol.* 2017, 118, 54–62. [CrossRef]

7. Ciombor, K.K.; Bekaii-Saab, T. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. *Oncologist* 2018, 23, 25–34. [CrossRef]

8. Koido, S.; Ohkusa, T.; Homma, S.; Namiki, Y.; Takakura, K.; Saito, K.; Ito, Z.; Kobayashi, H.; Kajihara, M.; Uchiyama, K.; et al. Immunotherapy for colorectal cancer. *World J. Gastroenterol.* 2013, 19, 8531–8542. [CrossRef]

9. Advani, S.; Kopetz, S. Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. *J. Surg. Oncol.* 2019, 119, 642–652. [CrossRef]

10. Overman, M.J.; Lonardi, S.; Wong, K.Y.M.; Lenz, H.J.; Gelsomino, F.; Aglietta, M.; Morse, M.A.; Van Cutsem, E.; McDermott, R.; Hill, A.; et al. Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J. Clin. Oncol.* 2018, 36, 773–779. [CrossRef]

11. Ciardiello, D.; Vitiello, P.P.; Cardone, C.; Martinelli, G.; Troiani, T.; Martinelli, E.; Ciardiello, F. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treat. Rev.* 2019, 76, 22–32. [CrossRef] [PubMed]

12. van der Stok, E.P.; Spaander, M.C.W.; Grunhagen, D.J.; Verhoef, C.; Kuipers, E.J. Surveillance after curative treatment for colorectal cancer. *Nat. Rev. Clin. Oncol.* 2017, 14, 297–315. [CrossRef]

13. Bonfrate, L.; Altomare, D.F.; Di Lena, M.; Travaglio, E.; Rotelli, M.T.; De Luca, A.; Portincasa, P. MicroRNA in colorectal cancer: New perspectives for diagnosis, prognosis and treatment. *J. Gastrointest. Liver Dis.* 2013, 22, 311–320.

14. Moussavi, S.; Moallem, R.; Hassanian, S.M.; Sadeghzade, M.; Mardani, R.; Ferns, G.A.; Khazaei, M.; Avan, A. Tumor-derived exosomes: Potential biomarkers and therapeutic target in the treatment of colorectal cancer. *J. Cell Physiol.* 2019, 234, 12422–12432. [CrossRef]

15. Wagner, S.; Mullins, C.S.; Linnebacher, M. Colorectal cancer vaccines: Tumor-associated antigens vsneoantigens. *World J. Gastroenterol.* 2018, 24, 5418–5432. [CrossRef] [PubMed]

16. Sermer, D.; Brentjens, R. CAR T-cell therapy: Full speed ahead. *Hematol. Oncol.* 2019, 37 (Suppl. 1), 95–100. [CrossRef] [PubMed]

17. Gross, G.; Waks, T.; Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc. Natl. Acad. Sci. USA* 1989, 86, 10024–10028. [CrossRef]

18. Dotti, G. The other face of chimeric antigen receptors. *Mol. Ther.* 2014, 22, 899–900. [CrossRef]

19. Maus, M.V.; Grupp, S.A.; Porter, D.L.; June, C.H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. *Blood* 2014, 123, 2625–2635. [CrossRef]

20. Quintas-Cardama, A. What CAR Will Win the CD19 Race? *Mol. Cancer Ther.* 2019, 18, 498–506. [CrossRef]

21. June, C.H.; Sadelain, M. Chimeric Antigen Receptor Therapy. *N. Engl. J. Med.* 2018, 379, 64–73. [CrossRef] [PubMed]

22. Brudno, J.N.; Kochenderfer, J.N. Chimeric antigen receptor T-cell therapies for lymphoma. *Nat. Rev. Clin. Oncol.* 2018, 15, 31–46. [CrossRef] [PubMed]

23. Zhang, C.; Liu, J.; Zhong, J.F.; Zhang, X. Engineering CAR-T cells. *Biomark. Res.* 2017, 5, 22. [CrossRef] [PubMed]

24. Turtle, C.J.; Hanafi, L.A.; Berger, C.; Gooley, T.A.; Cherian, S.; Hudecek, M.; Sommermeyer, D.; Melville, K.; Pender, B.; Budiarto, T.M.; et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *J. Clin. Investig.* 2016, 126, 2123–2138. [CrossRef]

25. Thistlethwaite, F.C.; Gilham, D.E.; Guest, R.D.; Rothwell, D.G.; Pillai, M.; Burt, D.J.; Byatte, A.J.; Kirillova, N.; Valle, J.W.; Sharma, S.K.; et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. *Cancer Immunol. Immunother.* 2017, 66, 1425–1436. [CrossRef]

26. Yeku, O.O.; Brentjens, R.J. Armored CAR T-cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. *Biochem. Soc. Trans.* 2016, 44, 412–418. [CrossRef]
27. Di, S.; Li, Z. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: Current status and future prospects. *Sci. China Life Sci.* 2016, 59, 360–369. [CrossRef]

28. Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.B.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.O.; Siddiqi, T.; Lin, Y.; et al. AxicabtageneCiloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N. Engl. J. Med.* 2017, 377, 2531–2544. [CrossRef]

29. Prasad, V. Immunotherapy: Tisagenlecleucel—the first approved CAR-T-cell therapy: Implications for payers and policy makers. *Nat. Rev. Clin. Oncol.* 2018, 15, 11–12. [CrossRef]

30. Lee, D.W.; Gardner, R.; Porter, D.L.; Louis, C.U.; Ahmed, N.; Jensen, M.; Grupp, S.A.; Mackall, C.L. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2014, 124, 188–195. [CrossRef]

31. Brudno, J.N.; Kochenderfer, J.N. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. *Blood Rev.* 2019, 34, 45–55. [CrossRef] [PubMed]

32. Bonifant, C.L.; Jackson, H.J.; Brentjens, R.J.; Curran, K.J. Toxicity and management in CAR T-cell therapy. *Mol. Ther.* 2016, 3, 16011. [CrossRef] [PubMed]

33. Davila, M.L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S.S.; Stefanis, J.; Borquez-Ojeda, O.; Olsezewska, M.; et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci. Transl. Med.* 2014, 6, 224ra225. [CrossRef] [PubMed]

34. Kochenderfer, J.N.; Dudley, M.E.; Kassim, S.H.; Somerville, R.P.; Carpenter, R.O.; Stetler-Stevenson, M.; Yang, J.C.; Phan, G.Q.; Hughes, M.S.; Sherry, R.M.; et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J. Clin. Oncol.* 2013, 35, 540–549. [CrossRef]

35. Teachey, D.T.; Lacey, S.F.; Shaw, P.A.; Melenhorst, J.J.; Maude, S.L.; Frey, N.; Pequignot, E.; Gonzalez, V.E.; Chen, F.; Finklestein, J.; et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia. *Cancer Dis.* 2016, 6, 664–679. [CrossRef]

36. Le, R.Q.; Li, L.; Yuan, W.; Shord, S.S.; Nie, L.; Habtemariam, B.A.; Przepiorka, D.; Farrell, A.T.; Pazdur, R. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. *Oncoesi* 2018, 23, 943–947. [CrossRef]

37. Hay, K.A. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. *Br. J. Haematol.* 2018, 183, 364–374. [CrossRef]

38. Hunter, B.D.; Jacobson, C.A. CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. *J. Natl. Cancer Inst.* 2019. [CrossRef]

39. Neelapu, S.S. Managing the toxicities of CAR T-cell therapy. *Hematol. Oncol.* 2019, 37 (Suppl. 1), 48–52. [CrossRef]

40. Shah, N.N.; Fry, T.J. Mechanisms of resistance to CAR T cell therapy. *Nat. Rev. Clin. Oncol.* 2019, 16, 372–385. [CrossRef]

41. Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; Maus, M.V.; Park, J.H.; Mead, E.; Pavletic, S.; et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol. Blood Marrow Transpl.* 2019, 25, 625–638. [CrossRef] [PubMed]

42. Hay, K.A.; Hanafi, L.A.; Li, D.; Gust, J.; Liles, W.C.; Wurfel, M.M.; Lopez, J.A.; Chen, J.; Chung, D.; Harju-Baker, S.; et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood* 2017, 130, 2295–2306. [CrossRef] [PubMed]

43. Morgan, R.A.; Yang, J.C.; Kitano, M.; Dudley, M.E.; Laurencot, C.M.; Rosenberg, S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol. Ther.* 2010, 18, 843–851. [CrossRef] [PubMed]

44. Minagawa, K.; Zhou, X.; Mineishi, S.; Di Stasi, A. Seatbelts in CAR therapy: How Safe Are CARS? *Pharmaceuticals* 2015, 8, 230–249. [CrossRef] [PubMed]

45. Tomuleasa, C.; Fuji, S.; Berce, C.; Onaciu, A.; Chira, S.; Petrushev, B.; Micu, W.T.; Moisoiu, V.; Osan, C.; Constantinescu, C.; et al. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. *Front. Immunol.* 2018, 9, 239. [CrossRef]

46. Shah, N.N.; Maatman, T.; Hari, P.; Johnson, B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. *Front. Oncol.* 2019, 9, 146. [CrossRef]
47. Gill, S.; Maus, M.V.; Porter, D.L. Chimeric antigen receptor T cell therapy: 25 years in the making. *Blood Rev.* 2016, 30, 157–167. [CrossRef]

48. Louis, C.U.; Savoldo, B.; Dotti, G.; Pule, M.; Yvon, E.; Myers, G.D.; Rossig, C.; Russell, H.V.; Diouf, O.; Liu, E.; et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood* 2011, 118, 6050–6056. [CrossRef]

49. Ahmed, N.; Brawley, V.S.; Hegde, M.; Robertson, C.; Ghazi, A.; Gerken, C.; Liu, E.; Dakhova, O.; Ashoori, A.; Corder, A.; et al. Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. *J. Clin. Oncol.* 2015, 33, 1688–1696. [CrossRef]

50. Feng, K.; Guo, Y.; Dai, H.; Wang, Y.; Li, X.; Jia, H.; Han, W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. *Sci. China Life Sci.* 2016, 59, 468–479. [CrossRef]

51. Scarfo, I.; Maus, M.V. Current approaches to increase CAR T cell potency in solid tumors: Targeting the tumor microenvironment. *J. Immunother. Cancer* 2017, 5, 28. [CrossRef] [PubMed]

52. Newick, K.; O’Brien, S.; Moon, E.; Albelda, S.M. CAR T Cell Therapy for Solid Tumors. *Annu. Rev. Med.* 2017, 68, 139–152. [CrossRef] [PubMed]

53. Yong, C.S.M.; Dardalhon, V.; Devaud, C.; Taylor, N.; Darcy, P.K.; Kershaw, M.H. CAR T-cell therapy of solid tumors. *Cell Biol. Int.* 2017, 41, 356–363. [CrossRef]

55. Wang, Z.; Wu, Z.; Liu, Y.; Han, W. New development in CAR-T cell therapy. *J. Hematol. Oncol.* 2018, 11, 22. [CrossRef]

56. Alrifai, D.; Sarker, D.; Maher, J. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. *Immunopharmacol. Immunotoxicol.* 2016, 38, 50–60. [CrossRef] [PubMed]

57. Cheng, X.; Zhao, G.; Zhao, Y. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. *Can J. Gastroenterol. Hepatol.* 2018, 2018, 6240467. [CrossRef] [PubMed]

58. Jindal, V.; Arora, E.; Masab, M.; Gupta, S. Chimeric antigen receptor T cell therapy in pancreatic cancer: From research to practice. *Med. Oncol.* 2018, 35, 84. [CrossRef]
68. Heckler, M.; Dougan, S.K. Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial. *Gastroenterology* 2018, 155, 11–14. [CrossRef]

69. Nichetti, F.; Marra, A.; Corti, F.; Guidi, A.; Raimondi, A.; Prinzi, N.; de Braud, F.; Pusceddu, S. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. *Target Oncol.* 2018, 13, 333–351. [CrossRef]

70. Batchu, R.B.; Gruzdyn, O.V.; Mahmud, E.M.; Chukr, F.; Dachepalli, R.; Manmari, S.K.; Mostafa, G.; Weaver, D.W.; Gruber, S.A. Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. *Surgery* 2018, 163, 627–632. [CrossRef]

71. Beatty, G.L.; O’Hara, M.H.; Lacey, S.F.; Torigian, D.A.; Nazimuddin, F.; Chen, F.; Kulikovskaya, I.M.; Soulen, M.C.; McGarvey, M.; Nelson, A.M.; et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology* 2018, 155, 29–32. [CrossRef] [PubMed]

72. Sun, Q.; Zhou, S.; Zhao, J.; Deng, C.; Teng, R.; Zhao, Y.; Chen, J.; Dong, J.; Yin, M.; Bai, Y.; et al. Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer. *Oncotarget* 2018, 9, 13694–13705. [CrossRef]

73. Watanabe, K.; Luo, Y.; Da, T.; Guedan, S.; Ruella, M.; Scholler, J.; Keith, B.; Young, R.M.; Engels, B.; Sorsa, S.; et al. Pancreatic cancer therapy with combined mesothelin-directed chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. *JCI Insight* 2018, 3. [CrossRef] [PubMed]

74. Mohammed, S.; Sukumaran, S.; Bajgain, P.; Watanabe, N.; Heslop, H.E.; Rooney, C.M.; Brenner, M.K.; Fisher, W.E.; Leen, A.M.; Vera, J.F. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. *Mol. Ther.* 2017, 25, 249–258. [CrossRef]

75. Abate-Daga, D.; Lagisetty, K.H.; Tran, E.; Zheng, Z.; Gattinoni, L.; Yu, Z.; Burns, W.R.; Miermont, A.M.; Teper, Y.; Rudloff, U.; et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. *Hum. Gene Ther.* 2014, 25, 1003–1012. [CrossRef] [PubMed]

76. Varghese, A.M. Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma. *Chin. Clin. Oncol.* 2017, 6, 66. [CrossRef]

77. Golubovskaya, V.; Berahovich, R.; Zhou, H.; Xu, S.; Harto, H.; Li, L.; Chao, C.C.; Mao, M.M.; Wu, L. CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. *Cancers* 2017, 9, 139. [CrossRef]

78. Zhang, E.; Yang, P.; Gu, J.; Wu, H.; Chi, X.; Liu, C.; Wang, Y.; Xue, J.; Qi, W.; Sun, Q.; et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. *J. Hematol. Oncol.* 2018, 11, 102. [CrossRef]

79. Raj, D.; Yang, M.H.; Rodgers, D.; Hampton, E.N.; Begum, J.; Mustafa, A.; Lorizio, D.; Garces, I.; Propper, D.; Kench, J.G.; et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. *Gut* 2019, 68, 1052–1064. [CrossRef]

80. Whilding, L.M.; Halim, L.; Draper, B.; Parente-Pereira, A.C.; Zabinski, T.; Davies, D.M.; Maher, J. CAR T-Cells Targeting the Integrin alphavbeta6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. *Cancers* 2019, 11, 674. [CrossRef]

81. Ali, A.I.; Oliver, A.J.; Samiei, T.; Chan, J.D.; Kershaw, M.H.; Garces, I.; Propper, D.; Kench, J.G.; et al. Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. *Front. Oncol.* 2019, 9, 56. [CrossRef] [PubMed]

82. Akce, M.; Zaidi, M.Y.; Waller, E.K.; El-Rayes, B.F.; Lesinski, G.B. The Potential of CAR T Cell Therapy in Pancreatic Cancer. *Front. Immunol.* 2018, 9, 2166. [CrossRef] [PubMed]

83. Hoseini, S.S.; Cheung, N.V. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. *Cancer Lett.* 2017, 399, 44–52. [CrossRef] [PubMed]

84. Ma, W.; Wu, L.; Zhou, F.; Hong, Z.; Yuan, Y.; Liu, Z. T Cell-Associated Immunotherapy for Hepatocellular Carcinoma. *Cell Physiol. Biochem.* 2017, 41, 609–622. [CrossRef]

85. Chen, Y.; Chang-Yong, E.; Gong, Z.W.; Liu, S.; Wang, Z.X.; Yang, Y.S.; Zhang, X.W. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. *Hepatobiliary Pancreat. Dis. Int.* 2018, 17, 301–309. [CrossRef]
86. Liu, Y.; Di, S.; Shi, B.; Zhang, H.; Wang, Y.; Wu, X.; Luo, H.; Wang, H.; Li, Z.; Jiang, H. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. *J. Immunol.* 2019, 203, 198–207. [CrossRef]

87. Jiang, Z.; Jiang, X.; Chen, S.; Lai, Y.; Wei, X.; Li, B.; Lin, S.; Wang, S.; Wu, Q.; Liang, Q.; et al. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. *Front. Immunol.* 2016, 7, 690. [CrossRef]

88. Gao, H.; Li, K.; Tu, H.; Pan, X.; Jiang, H.; Shi, B.; Kong, J.; Wang, H.; Yang, S.; Gu, J.; et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. *Clin. Cancer Res.* 2014, 20, 6418–6428. [CrossRef]

89. Chen, C.; Li, K.; Jiang, H.; Song, F.; Gao, H.; Pan, X.; Shi, B.; Bi, Y.; Wang, H.; Li, Z. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. *Cancer Immunol. Immunother.* 2016, 66, 475–489. [CrossRef]

90. Guo, X.; Jiang, H.; Shi, B.; Zhou, M.; Zhang, H.; Shi, Z.; Du, G.; Luo, H.; Wu, X.; Wang, Y.; et al. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. *Front. Pharmacol.* 2018, 9, 1118. [CrossRef]

91. Zhang, R.; Zhang, Z.; Liu, Z.; Wei, D.; Wu, X.; Bian, H.; Chen, Z. Adoptive cell transfer therapy for hepatocellular carcinoma. *Front. Med.* 2019, 13, 3–11. [CrossRef] [PubMed]

92. Mizukoshi, E.; Kaneko, S. Immune cell therapy for hepatocellular carcinoma. *J. Hematol. Oncol.* 2019, 12, 52. [CrossRef] [PubMed]

93. Han, H.; Wang, S.; Hu, Y.; Li, Z.; Yang, W.; Lv, Y.; Wang, L.; Zhang, L.; Ji, J. Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer. *OncoLett.* 2018, 15, 6887–6894. [CrossRef] [PubMed]

94. Kim, M.; Pyo, S.; Kang, C.H.; Lee, C.O.; Lee, H.K.; Choi, S.U.; Park, C.H. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. *PLoS ONE* 2018, 13, e0198347. [CrossRef] [PubMed]

95. Tao, K.; He, M.; Tao, F.; Xu, G.; Ye, M.; Zheng, Y.; Li, Y. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. *Cancer Chemother. Pharmacol.* 2018, 82, 815–827. [CrossRef] [PubMed]

96. Jiang, H.; Shi, Z.; Wang, P.; Wang, C.; Yang, L.; Du, G.; Zhang, H.; Shi, B.; Jia, J.; Li, Q.; et al. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. *J. Natl. Cancer Inst.* 2019, 111, 409–418. [CrossRef]

97. Kiesgen, S.; Chicaybam, L.; Chintala, N.K.; Adusumilli, P.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. *J. Thorac. Oncol.* 2018, 13, 16–26. [CrossRef]

98. Shi, H.; Yu, F.; Mao, Y.; Ju, Q.; Wu, Y.; Bai, W.; Wang, P.; Xu, R.; Jiang, M.; Shi, J. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. *J. Thorac. Dis.* 2018, 10, 2779–2788. [CrossRef]

99. DeLeon, T.T.; Zhou, Y.; Nagalo, B.M.; Yokoda, R.T.; Ahn, D.H.; Ramanathan, R.K.; Salomao, M.A.; Aqel, B.A.; Mahipal, A.; Bekaii-Saab, T.S.; et al. Novel immunotherapy strategies for hepatobiliary cancers. *Immunotherapy* 2018, 10, 1077–1091. [CrossRef]

100. Xu, J.Y.; Ye, Z.L.; Jiang, D.Q.; He, J.C.; Ding, Y.M.; Li, L.F.; Lv, S.Q.; Wang, Y.; Jin, H.J.; Qian, Q.J. Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. *Tumour Biol.* 2017, 39, 10104283177695949. [CrossRef]

101. Gao, Y.; Feng, K.; Liu, Y.; Wu, Z.; Dai, H.; Yang, Q.; Wang, Y.; Jia, H.; Han, W. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. *Clin. Cancer Res.* 2018, 24, 1277–1286. [CrossRef] [PubMed]

102. Feng, K.C.; Guo, Y.L.; Liu, Y.; Dai, H.R.; Wang, Y.; Lv, H.Y.; Huang, J.H.; Yang, Q.M.; Han, W.D. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. *J. Hematol. Oncol.* 2017, 10, 4. [CrossRef] [PubMed]

103. Yan, M.; Schweaderle, M.; Arguello, D.; Millis, S.Z.; Gatalica, Z.; Kurzrock, R. HER2 expression status in diverse cancers: Review of results from 37,992 patients. *Cancer Metastasis Rev.* 2015, 34, 157–164. [CrossRef] [PubMed]
104. Hege, K.M.; Bergsland, E.K.; Fisher, G.A.; Nemunaitis, J.J.; Warren, R.S.; McArthur, J.G.; Lin, A.A.; Schlom, J.; June, C.H.; Sherwin, S.A. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. *J. Immunother. Cancer* 2017, 5, 22. [CrossRef] [PubMed]

105. Magee, M.S.; Kraft, C.L.; Abraham, T.S.; Baybutt, T.R.; Marszalowicz, G.P.; Li, P.; Waldman, S.A.; Snook, A.E. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. *Oncoimmunology* 2016, 5, e1227897. [CrossRef] [PubMed]

106. Magee, M.S.; Abraham, T.S.; Baybutt, T.R.; Flickinger, J.C., Jr; Ridge, N.A.; Marszalowicz, G.P.; Prajapati, P.; Hersperger, A.R.; Waldman, S.A.; Snook, A.E. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. *Cancer Immunol. Res.* 2018, 6, 509–516. [CrossRef]

107. Sheen, A.J.; Irlam, J.; Kirillova, N.; Guest, R.D.; Sherlock, D.J.; Hawkins, R.E.; Gilmour, T.E. Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. *Dis. Colon. Rectum.* 2003, 46, 793–804. [CrossRef]

108. Zhang, C.; Wang, Z.; Yang, Z.; Wang, M.; Li, S.; Li, Y.; Zhang, R.; Xiong, Z.; Wei, Z.; Shen, J.; et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA (+) Metastatic Colorectal Cancers. *Mol. Ther.* 2017, 25, 1248–1258. [CrossRef]

109. Blat, D.; Zigmund, E.; Alteber, Z.; Waks, T.; Eshhar, Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. *Mol. Ther.* 2014, 22, 1018–1028. [CrossRef]

110. Chi, X.; Yang, P.; Zhang, E.; Gu, J.; Xu, H.; Li, M.; Gao, X.; Li, X.; Zhang, Y.; Hu, J. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. *Cancer Med.* 2019, 8, 4753–4765. [CrossRef]

111. Darcy, P.K.; Haynes, N.M.; Snook, M.B.; Trapani, J.A.; Cerruti, L.; Jane, S.M.; Smyth, M.J. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. *J. Immunol.* 2000, 164, 3705–3712. [CrossRef] [PubMed]

112. Simmons, A.; Whitehead, R.P.; Kolokoltsov, A.A.; Davey, R.A. Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro. *Virol. J.* 2006, 3, 8. [CrossRef] [PubMed]

113. Mardiana, S.; John, L.B.; Henderson, M.A.; Slaney, C.Y.; von Scheidt, B.; Giuffrida, L.; Davenport, A.J.; Trapani, J.A.; Neeson, P.J.; Loi, S.; et al. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. *Cancer Res.* 2017, 77, 1296–1309. [CrossRef] [PubMed]

114. Daly, T.; Royal, R.E.; Kershaw, M.H.; Treisman, J.; Wang, G.; Li, W.; Herlyn, D.; Eshhar, Z.; Hwu, P. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. *Cancer Gene Ther.* 2000, 7, 284–291. [CrossRef] [PubMed]

115. Huang, Q.; Xi, J.; Wang, L.; Wang, X.; Ma, X.; Deng, Q.; Lu, Y.; Kumar, M.; Zhou, Z.; Li, L.; et al. Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. *J. Hematol. Oncol.* 2018, 11, 90. [CrossRef]

116. Katz, S.C.; Point, G.R.; Cunetta, M.; Thorn, M.; Guha, P.; Espat, N.J.; Boutros, C.; Hanna, N.; Junghans, R.P. Regional CAR-T cell infusions for periportal carcinoma are superior to systemic delivery. *Cancer Gene Ther.* 2016, 23, 142–148. [CrossRef]

117. Ang, W.X.; Li, Z.; Chi, Z.; Du, S.H.; Chen, C.; Tay, J.C.; Toh, H.C.; Connolly, J.E.; Xu, X.H.; Wang, S. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. *Oncotarget* 2017, 8, 13345–13359. [CrossRef]

118. Zhang, B.L.; Li, D.; Gong, Y.L.; Huang, Y.; Qin, D.Y.; Jiang, L.; Liang, X.; Yang, X.; Gou, H.F.; Wang, Y.S.; et al. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. *Hum. Gene Ther.* 2019, 30, 402–412. [CrossRef] [PubMed]

119. Deng, X.; Gao, F.; Li, N.; Li, Q.; Zhou, Y.; Yang, T.; Cai, Z.; Du, P.; Chen, F.; Cai, J. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo. *Am. J. Cancer Res.* 2019, 9, 945–958. [CrossRef]

120. Teng, R.; Zhao, J.; Zhao, Y.; Gao, J.; Li, H.; Zhou, S.; Wang, Y.; Sun, Q.; Lin, Z.; Yang, W.; et al. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model. *J. Immunother.* 2019, 42, 33–42. [CrossRef]
121. Katlinski, K.V.; Gui, J.; Katlinskaya, Y.V.; Ortiz, A.; Chakraborty, R.; Bhattacharya, S.; Carbone, C.J.; Beiting, D.P.; Girondo, M.A.; Peck, A.R.; et al. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. *Cancer Cell* 2017, 31, 194–207. [CrossRef] [PubMed]

122. Wang, Y.; Chen, M.; Wu, Z.; Tong, C.; Dai, H.; Guo, Y.; Liu, Y.; Huang, J.; Lv, H.; Luo, C.; et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. *Oncoimmunology* 2018, 7, e1440169. [CrossRef] [PubMed]

123. Kuczma, M.P.; Ding, Z.C.; Li, T.; Habtetsion, T.; Chen, T.; Hao, Z.; Bryan, L.; Singh, N.; Kochenderfer, J.N.; Zhou, G. The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. *Oncotarget* 2017, 8, 111931–111942. [CrossRef] [PubMed]

124. Ren-Heidenreich, L.; Mordini, R.; Hayman, G.T.; Siebenlist, R.; LeFever, A. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. *Cancer Immunol. Immunother.* 2002, 51, 417–423. [CrossRef] [PubMed]

125. Sasaki, T.; Ikeda, H.; Sato, M.; Ohkuri, T.; Abe, H.; Kuroki, M.; Onodera, M.; Miyamoto, M.; Kondo, S.; Nishimura, T. Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. *Cancer Sci.* 2006, 97, 920–927. [CrossRef]

126. alloSHRINK-Standard Chemotherapy Regimen and Immunotherapy with Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cell-Full Text View-ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03692429 (accessed on 13 August 2019).

127. EGFR-IL12-CART Cells for Patients with Metastatic Colorectal Cancer-Full Text View-ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03542799 (accessed on 20 December 2019).

128. EGFR CART Cells for Patients with Metastatic Colorectal Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT03152435 (accessed on 20 December 2019).

129. A Study of Chimeric Antigen Receptor T Cells Combined with Intervventional Therapy in Advanced Liver Malignancy. Available online: https://clinicaltrials.gov/ct2/show/NCT02959151 (accessed on 20 December 2019).

130. Hepatic Transarterial Administrations of NKR-2 in Patients with Unresectable Liver Metastases from Colorectal Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT03370198 (accessed on 20 December 2019).

131. Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently with FOLFOX in Colorectal Cancer with Potentially Resectable Liver Metastases. Available online: https://clinicaltrials.gov/ct2/show/NCT03310008 (accessed on 20 December 2019).

132. CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor-Full Text View-ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT02617134 (accessed on 14 August 2019).

133. A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer-Full Text View-ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT02713984 (accessed on 14 August 2019).

134. A Clinical Research of CAR T Cells Targeting CEA Positive Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT02349724 (accessed on 20 December 2019).

135. CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC). Available online: https://clinicaltrials.gov/ct2/show/NCT03682744 (accessed on 18 December 2019).

136. Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies-Tabular View-ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03638206 (accessed on 14 August 2019).

137. A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer-Full Text View-ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03013712 (accessed on 14 August 2019).

138. Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 [Internet]. Available online: https://clinicaltrials.gov/ct2/show/record/NCT02541370?cond=Colorectal+Cancer&intr=chimeric+antigen+receptor+t-cell&rank=13 (accessed on 9 July 2019).

139. CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT02850536 (accessed on 19 December 2019).
140. Binary Oncolytic Adenovirus in Combination with HER2-Specific CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)-Full Text View-ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03740256 (accessed on 14 August 2019).

141. CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases. Available online: https://clinicaltrials.gov/ct2/show/NCT02416466 (accessed on 20 December 2019).

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).